The ECEL1 Knockout HeLa Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population in which the human ECEL1 gene has been disrupted. This heterogeneous loss-of-function tool, generated via CRISPR/Cas9-mediated gene targeting, provides an accessible model for studying ECEL1??s role in neuropeptide processing without the requirement for clonal isolation. The polyclonal nature preserves genetic diversity while ensuring targeted gene disruption across the population, serving as a versatile system for functional genomics and drug discovery applications.
HeLa cells are an immortalized human epithelial cell line derived from a cervical adenocarcinoma of Henrietta Lacks in 1951. Widely used in biomedical research, they are characterized by aneuploidy and HPV18 integration, which drive their continuous proliferation. Their epithelial origin and robust growth make them ideal for transfection and large-scale culture. As a non-neuronal line, HeLa cells allow the biochemical dissection of ECEL1 function decoupled from neuronal differentiation programs, offering a simplified context to investigate metalloprotease activity.
ECEL1 encodes a type II transmembrane metalloprotease that processes neuropeptides such as substance P and neurotensin within the secretory pathway. Its expression is governed by the neurogenic transcription factors SOX10 and PAX3, linking it to neural crest development. Upon cleavage, mature neuropeptides activate receptors like the neurokinin 1 receptor (NK1R), triggering second messenger cascades involving cAMP and Ca2?. ECEL1 physically interacts with its substrates and secretory pathway components. Loss of function disrupts neuropeptide maturation, contributing to the motor deficits observed in distal arthrogryposis type 5D and related neuropathies.
Within HeLa cells, this ECEL1 knockout population enables investigation of metalloprotease activity and substrate processing in a tractable system. Although HeLa cells are epithelial and do not endogenously express neuropeptides, they can be engineered to express neuropeptide precursors, reconstituting the cleavage pathway. This approach facilitates dissection of ECEL1??s catalytic mechanism, substrate specificity, and regulation by secretory trafficking. The model also supports phenotypic screening for small-molecule modulators of metalloprotease function.
Typical assays include western blotting and RT-qPCR to verify ECEL1 disruption, protease activity assays using fluorogenic substrates, and neuropeptide cleavage assays with recombinant substrates. Immunofluorescence can localize ECEL1 and assess trafficking, while cell viability assays can probe functional outcomes. This knockout product is valuable for disease modeling of distal arthrogryposis and for screening metalloprotease inhibitors or activators. For additional information, please contact Ascent Research.
